These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 3464101)

  • 1. Gallium citrate Ga 67 accumulation in pulmonary lesions after chemotherapy (MOPP).
    Wells JD; Huskison WT; Davenport OL
    South Med J; 1986 Oct; 79(10):1293-6. PubMed ID: 3464101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of MOPP chemotherapy in early stage Hodgkin's disease.
    Mauch P; Hellman S
    Hematol Oncol; 1984; 2(1):66-9. PubMed ID: 6376318
    [No Abstract]   [Full Text] [Related]  

  • 3. MOPP, ABVD, or both to treat Hodgkin's disease.
    Aisenberg AC
    N Engl J Med; 1993 Apr; 328(14):1045; author reply 1045-6. PubMed ID: 7680765
    [No Abstract]   [Full Text] [Related]  

  • 4. Two cycles of MOPP and definitive radiotherapy for stage IIIA and IIIB Hodgkin's disease.
    Fuller LM; Hagemeister FB
    Recent Results Cancer Res; 1989; 117():197-204. PubMed ID: 2602645
    [No Abstract]   [Full Text] [Related]  

  • 5. Is ABVD the standard regimen for Hodgkin's disease based on randomized CALGB comparison of MOPP, ABVD and MOPP alternating with ABVD?
    Canellos GP
    Leukemia; 1996 Jun; 10 Suppl 2():s68. PubMed ID: 8649055
    [No Abstract]   [Full Text] [Related]  

  • 6. Mediastinal Hodgkin's disease. Significance of mediastinal involvement in early stage Hodgkin's disease.
    Mauch P; Hellman S
    Hematol Oncol; 1984; 2(1):69-72. PubMed ID: 6547403
    [No Abstract]   [Full Text] [Related]  

  • 7. Recovery of spermatogenesis after treatment for Hodgkin's disease: limiting dose of MOPP chemotherapy.
    da Cunha MF; Meistrich ML; Fuller LM; Cundiff JH; Hagemeister FB; Velasquez WS; McLaughlin P; Riggs SA; Cabanillas FF; Salvador PG
    J Clin Oncol; 1984 Jun; 2(6):571-7. PubMed ID: 6547167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized study for the treatment of adult advanced Hodgkin's disease: mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) versus lomustine, vinblastine, and prednisone.
    Liebman HA; Hum GJ; Sheehan WW; Ryden VM; Bateman JR
    Cancer Treat Rep; 1983 May; 67(5):413-9. PubMed ID: 6342771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MOPP chemotherapy versus extended-field radiotherapy in the management of pathological stages I-IIA Hodgkin's disease.
    Cimino G; Biti GP; Anselmo AP; Maurizi Enrici R; Bellesi GP; Bosi A; Cionini L; Mungai V; Papa G; Ponticelli P
    J Clin Oncol; 1989 Jun; 7(6):732-7. PubMed ID: 2715803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pulmonary toxicity following MOPP chemotherapy.
    Millward MJ; Cohney SJ; Byrne MJ; Ryan GF
    Aust N Z J Med; 1990 Jun; 20(3):245-8. PubMed ID: 2196871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunoblastic lymphoma following therapy for Hodgkin's disease. A case report.
    Casini M; Pianezze G; Fabris P; Cemin S; Coser P
    Haematologica; 1986; 71(1):50-2. PubMed ID: 3084357
    [No Abstract]   [Full Text] [Related]  

  • 12. BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study.
    Bakemeier RF; Anderson JR; Costello W; Rosner G; Horton J; Glick JH; Hines JD; Berard CW; DeVita VT
    Ann Intern Med; 1984 Oct; 101(4):447-56. PubMed ID: 6089632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
    Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C
    Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low risk of secondary leukemias after chemotherapy without mechlorethamine in childhood Hodgkin's disease. German-Austrian Pediatric Hodgkin's Disease Group.
    Schellong G; Riepenhausen M; Creutzig U; Ritter J; Harbott J; Mann G; Gadner H
    J Clin Oncol; 1997 Jun; 15(6):2247-53. PubMed ID: 9196137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized study for the treatment of advanced Hodgkin's disease: MOPP vs. LOPP.
    Avilés A; Díaz-Maqueo JC; García EL; Torras V; López-Vancell D
    Arch Invest Med (Mex); 1991; 22(1):45-50. PubMed ID: 1819976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of childhood Hodgkin's disease without radiotherapy.
    van den Berg H; Zsiros J; Behrendt H
    Ann Oncol; 1997; 8 Suppl 1():15-7. PubMed ID: 9187423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteonecrosis of sternum and rib in a patient treated for Hodgkin's disease.
    Blijham GH; Vermeulen A; Mendes de Leon DE
    Cancer; 1985 Nov; 56(9):2292-4. PubMed ID: 3840407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial.
    Glick JH; Young ML; Harrington D; Schilsky RL; Beck T; Neiman R; Fisher RI; Peterson BA; Oken MM
    J Clin Oncol; 1998 Jan; 16(1):19-26. PubMed ID: 9440718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Myocardial infarct in a patient with Hodgkin's disease treated with cyclic polychemotherapy].
    Matusewicz W; Drzewoski J; Robak T; Krykowski E
    Kardiol Pol; 1983; 26(7):591-4. PubMed ID: 6689036
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of adriamycin-containing chemotherapy (MOP-BAP) with MOPP-Bleomycin in the management of advanced Hodgkin's disease. A Southwest Oncology Group Study.
    Jones SE; Haut A; Weick JK; Wilson HE; Grozea P; Fabian CJ; McKelvey E; Byrne GE; Hartsock R; Dixon DO; Coltman CA
    Cancer; 1983 Apr; 51(8):1339-47. PubMed ID: 6186355
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.